Pfizer's Lyrica meets endpoint in Ph III study of central neuropathic pain after spinal cord injury

Global drugs behemoth Pfizer (NYSE: PFE) says its blockbuster neuropathic pain drug Lyrica (pregabalin) met its primary endpoint of positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo in a Phase III study. Further analysis will be conducted on these initial results, the firm added.

“We are pleased with the top-line results of this study and look forward to more fully understanding the benefit that Lyrica may bring to these patients,” said Steven Romano, senior vice president, Head, Medicines Development Group, Global Primary Care Business Unit, at Pfizer.

Study A0081107 was a randomized, double-blind, placebo-controlled, parallel group, multi-center study comparing pregabalin flexibly dosed (150-600mg/day, dosed twice-daily) and placebo in subjects with chronic Central Neuropathic Pain following traumatic spinal cord injury. A total of 220 subjects were enrolled in the study (112 pregabalin and 108 placebo) in 66 investigative sites in 10 countries.